AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference

March 13, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 13, 2019--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29 th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York City, NY.

A webcast of the presentation will be available in the Investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005120/en/

CONTACT: Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

amatthews@catabasis.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Catabasis Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 03/13/2019 08:00 AM/DISC: 03/13/2019 08:01 AM

http://www.businesswire.com/news/home/20190313005120/en